Form 4: Acumen Pharmaceuticals COO Sells Shares to Cover Tax Obligations

Russell Barton, COO of Acumen Pharmaceuticals, sold 2,914 shares of common stock on January 21, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• Russell Barton, the Chief Operating Officer of Acumen Pharmaceuticals, sold 2,914 shares of the company's common stock on January 21, 2025.
• The sale was executed at a weighted average price of $1.6102 per share, with individual transactions ranging from $1.6100 to $1.6150.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 31, 2024.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Barton directly owns 136,117 shares of Acumen Pharmaceuticals.
• The sale was reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sale of shares to cover taxes) by an executive, which is neither particularly positive nor negative. The use of a 10b5-1 plan suggests proper governance.

Industry Context

Sales to cover tax obligations are a common practice among executives receiving equity compensation. The use of a 10b5-1 plan suggests the executive planned the sale in advance to avoid insider trading concerns.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Acumen Pharmaceuticals, ABOS, Russell Barton, Chief Operating Officer, Form 4, Stock Sale, Rule 10b5-1, Tax Obligations, Restricted Stock Units, Insider Trading